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Abstract 
Purpose: To develop and validate a new high performance liquid chromatographic (HPLC) method for 
the simultaneous determination of isoniazid (INH) and pyrazinamide (PZA) in plasma. 
Methods: A 150 µL aliquot of plasma was mixed with 75 µL of 10 % trichloroacetic acid containing 100 
mg/L of acetanilide as the internal standard (IS). After vortex mixing and centrifugation, 100 µL of the 
supernatant was reacted with 20 µL of 0.1 % trans-cinnamaldehyde for 10 min, and then 40 µL of 1M 
ammonium acetate was added. Finally, 20 µL was injected into the HPLC system. HPLC analysis was 
performed on reversed phase C18 column. The initial composition of the mobile phase was 4 % 
acetonitrile, and 96 % of 20 mM 1-hexane sulfonic acid (PH 2.7) delivered at a flow rate 1 mL/min.  
Results: All calibration curves were linear (r2 > 0.997). The method was accurate, and relative error 
(RE) was < 4.5 % for both drugs. Intra-day and inter-day precision was good for both drugs, with the 
highest relative standard deviation (RSD) being 8.51 %. The lower limit of quantification was 0.60 mg/L 
for isoniazid and 3.00 mg/L for pyrazinamide. 
Conclusion: The method proposed here is precise, accurate, fast, simple and suitable for therapeutic 
drug monitoring of INH and PZA simultaneously. 
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Isoniazid (INH), rifampicin (RIF), and 
pyrazinamide (PZA) are the mainstay drugs in 
the treatment of tuberculosis (TB). Isoniazid is 
the most powerful anti-tuberculosis agent against 
the rapidly dividing organism because it 
possesses the highest early bactericidal activity 
(EBA) [1,2]. Although pyrazinamide has no or 
little EBA, it has a high-sterilizing activity [2]. PZA 
is particularly effective against the 
Mycobacterium tuberculosis in the area of 
necrosis, where acidic media are available. In 
vitro studies show that both PZA and INH exhibit 
a concentration-dependent effect [3,4]. Poor 
patient outcomes were associated with low levels 
of INH or PZA [5-7]. Thus, individualization of 
INH and PZA doses based on their blood 
concentration could be helpful in optimizing the 
drug therapy for some patients with poor 
response. 
 
Several HPLC methods for the determination of 
one or more of the antituberculosis drugs in 
plasma or serum are available [8-13]. Some of 
these methods are developed for determining 
INH alone or with its major metabolites [8-11]; as 
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a result, these methods cannot be applied for 
determination of PZA. HPLC methods for 
simultaneous determination of INH, PZA, and 
RIF are also available [12,13].  In the present 
work, we describe a new HPLC method with UV 
detection for simultaneous determination of INH 
and PZA in plasma. The advantages of this 
method include the following: (1) a small volume 
of plasma is required; (2) sample pretreatment is 
simple; (3) the method is time efficient because 
the drying and reconstitution steps are omitted, 
and HPLC run time is short; and (4) 
simultaneous determination of INH and PZA is 
accomplished. This method is proven to be 
simple, fast, selective, accurate, and precise and 
was successfully applied for the determination of 
INH and PZA plasma concentrations in 




Reagents and chemicals 
 
Reagents with high purities were purchased from 
well-established and global suppliers to ensure 
accurate and precise results in the present study. 
INH, PZA acetanilide, trans-cinnamaldehyde, 
ammonium acetate, and trichloroacetic acid 
(TCA) were purchased from Sigma-Aldrich 
(Germany). The purity of all of these chemicals 
was above 99 %. HPLC-grade 1-hexane sulfonic 
acid sodium salt was purchased from Fisher 
Scientific (UK).  HPLC-grade acetonitrile was 
purchased from J.T. Baker (China). Deionized 
water was obtained from Direct-Q UV3 (Millipore, 
France). A stock solution of 0.1 % trans-
cinnamaldehyde was prepared by diluting the 




The HPLC system consists of 1525 binary 
pumps (Waters), 2489 UV/Visible detector 
(Waters),  7125 Rheodyne Manuel injector, 
which were connected by 20 µL stainless steel 
tubes to Zorbax Eclipse Plus C18 column (150 × 
4.6 mm, 5 µm particle size) equipped with 
Zorbax C18 guard column.  The mobile phase 
consists of HPLC grade acetonitrile as solvent A 
and 20 mM 1-hexane sulfonic acid sodium salt 
(pH 2.7, adjusted with 10 % ortho-phosphoric 
acid) as solvent B.  
 
The mobile phase was delivered as gradient 
elution, which started as 4 % solvent A and 96 % 
solvent B at a flow rate of 1 mL/min, for the first 
4.5 min. Then, the percentage of acetonitrile and 
the flow rate were increased linearly to reach 35 
% and 1.5 mL/min respectively, by 5.5 min. This 
later setting was held until 8.5 min. After that, the 
percentage of acetonitrile was further increased 
linearly to reach 50 % by 9.5 min.  Finally, 
acetonitrile percentage and the flow rate were 
decreased linearly to reach the initial setting by 
10 min and were kept stable to the end of the run 
at 13 min. The volume of injection was 20 µL. By 
programming the timed-event feature of the 
detector, which allows changing the wave 
lengths, the signals were monitored at 269, 254 
and 340 nm for PZA, acetanilide and INH trans-
cinnamaldehyde derivative respectively. 
 
Preparation of standards and quality control 
samples 
 
Stock solutions of INH, PZA and acetanilide were 
prepared in purified water at concentration of 1 
g/L. These stock solutions were kept in amber 
glass bottles and stored at −20 °C. Calibration 
standards (CS) of 3, 10, 20, 30, 60, 75 mg/L of 
PZA and 0.6, 2, 4, 6, 12, 15 mg/L of INH were 
prepared in a volumetric flask by spiking blank 
human plasma with an appropriate amount of the 
stock solutions. Quality control samples (QCS) 
were prepared by spiking the blank human 
plasma with the appropriate amount of the stock 
solutions of PZA and INH to produce QCS of low 
concentration (8 mg/L PZA and 1.6 mg/L INH), 
middle concentration (35 mg/L PZA and 7 mg/L 
INH), and high concentration (70 mg/L PZA and 
14 mg/L INH). Acetanilide as internal standard 
(IS) was prepared at 100 mg/L concentration in 




One hundred and fifty micro-liter (150 µL) of 
plasma was placed in 1.5 mL microcentrifuge 
tube, and 75 µL of 100 mg/L of IS in 10 % TCA 
was added. After mixing on a vortex shaker for 
20 s, the mixture was centrifuged at 3000 rpm for 
7 min. To a 100 µL aliquot of the supernatant, 20 
µL of 0.1 % trans-cinnamaldehyde in methanol 
was added and left for 10 min. Then, 40 µL of 1 
M ammonium acetate was added to neutralize 
pH. Finally, 20 µL solution was injected into the 
HPLC system. 
 
Method validation  
 
Selectivity:  Selectivity of the method was 
assessed by analyzing six different batches of 
pooled human plasma. 
 
Calibration curves: For INH, the calibration curve 
was constructed by plotting the ratio of peak 
height of INH to the peak height of IS (y-axis) 
against the nominal concentrations of the six INH 
CS (x-axis). For PZA, the calibration curve was 
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constructed by plotting the ratio of peak area of 
PZA to the peak area of IS (y-axis) against the 
nominal concentrations of the six PZA CS (x-
axis). Least square linear regression was 
employed to generate the calibration equations 
and the correlation coefficients. 
 
Limit of detection (LOD) and of lower limit of 
quantification (LLOQ): LOD was defined as the 
lowest concentration with a signal-to-noise (S/N) 
ratio of at least 3. LLOQ was defined as the 
lowest concentration on the calibration curve with 
at least five times greater response than that of 
blank plasma, a precision of < 20 % and 
accuracy within ± 20 %. 
 
Accuracy and precision:  The three QCS and the 
LLOQ for each drug were injected five times daily 
to assess the accuracy and intra-day precision. 
This process was repeated for three consecutive 
days to assess the inter-day precision and 
accuracy. Accuracy was measured as the 
relative error (RE, %), and precision was 
measured as the relative standard deviation 
(RSD, %). 
 
Recovery: Recovery was assessed by comparing 
the peak's area of the three QCS of PZA in the 
plasma, with their corresponding concentration in 
the post-extracted plasma. Recovery of INH was 
assessed by comparing the peak's height of the 
three QCS in the plasma with their corresponding 
concentration in the post-extracted plasma. 
Recovery of the IS was assessed by comparing 
its peak's area at 100 mg/L concentration spiked 
in the plasma with the same concentration spiked 
in post-extracted plasma. Five replicates of each 
concentration were conducted. 
 
Ethical approval  
 
Before the application of this method to TB 
patients, ethical approval was obtained from the 
Medical Research and Ethic Committee (MREC), 
Ministry of Health Malaysia (approval ref no. 
KKM/NIHSEC/P11-569). The study was 
conducted in compliance with the Declaration of 
Helsinki [14]. Every enrolled patient was given an 
informed consent form written in either Malay 
language or English languages. The patients had 
to sign the informed consent form, in order to be 
accepted in the study. Verbal clarification was 






Under the programmatic gradient elution 
described previously, when the acetonitrile 
percentage was kept at 4 %, PZA eluted at 4 
min. The retention time of PZA could be 
shortened by increasing the percentage of 
acetonitrile in the mobile phase. However, we 
found that, this composition is the optimum, 
considering peak symmetry and peak area. By 
increasing the percentage of acetonitrile in the 
mobile phase, acetanilide, and INH trans-
cinnamaldehyde derivative eluted at 
approximately 7.5 and 8.5 min, respectively. The 
chromatogram of   blank plasma (Figure 1), 
plasma spiked with the specific concentrations of 
PZA (Figure 2) and INH (Figure 2), and plasma 
from TB patients (Figure 3) are provided. 
 
Method validation  
 
For method selectivity, the six different batches 
of human plasma did not exhibit any interfering 
peaks at, or close to, the retention time of PZA, 
IS, or INH. 
 
The calibration equation of the calibration curves 
of PZA in the range of 3 mg/L to 75 mg/L was y = 
(0.041 ± 0.005) x + (0.009 ± 0.009), r2 = (0.999 ± 
0.00) (n = 3). The calibration equation of the 
calibration curves of INH in the range of 0.6 mg/L 
to 15 mg/L was y = (0.063± 0.006) x + (0.0096 ± 
0.003), r2 = (0.9986 ± 0.0005) (n = 3). 
 
 
     Figure 1: Typical chromatogram of blank plasma 
 
 = 340 nm 
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          Figure 2: Typical chromatogram of plasma spiked with 30 mg/L PZA, and 6 mg/L INH 
 
 
           Figure 3: Typical chromatogram of tuberculosis patient's plasma 
 
The deviation of all CS used in constructing the 
calibration curves for INH or PZA from their 
nominal concentration was < 15 %. The LOD 
was 1 mg/L for PZA and 0.25 mg/L for INH. The 
LLOQ was set at 3 mg/L for PZA and 0.6 mg/L 
for INH. The intraday and interday results show 
good accuracy and precision for PZA and INH. 
For PZA, intraday and interday accuracy (RE, %) 
were between −3.2 % and 3.7 % and between 
−3.2 % and 1.1 %, respectively; meanwhile, its 
intraday and interday precision (RSD, %) were 
not more than 7.3 % and not more than 7.9 %, 
respectively. For INH, intraday and interday 
accuracy (RE, %) were from −2.1 % to 4.2 % and 
from −3.4 % to 2.3 %, respectively; meanwhile, 
its intraday and interday precision (RSD, %) were 
not more than 4.38 % and not more than 8.5 %, 
respectively (Table 1). 
 
The average recoveries of PZA and INH were 91 
% (RSD, 3.64 %) and 96.28 % (RSD, 5.4 %), 
respectively. Meanwhile, the recovery of IS was 
87.3 % (Table 2). 
 
Application of the method to TB patients 
 
The method was applied to determine the 
plasma concentrations of INH and PZA in 25 
HIV-negative, pulmonary TB patients treated in 
Hospital Pulau Pinang, Malaysia. All patients 
were in the intensive phase of therapy. Drugs 
were given in doses based on the body weight of 
the patients. Five blood samples were collected 
from each patient in evacuated blood collection 
tubes containing ethylenediaminetetraacetic acid 
(EDTA) at 0.5, 1, 2, 3, and 4 h after witnessed 
administration of anti-TB agents. Plasma was 
separated immediately and stored in the freezer 
at −20 °C until the analysis. A wide variation in 
maximum blood concentrations (Cmax) of INH and 
PZA, as well as time to reach Cmax (Tmax), was 
observed. 
 
Table 1: Intra- and inter-day accuracy and precision of the proposed method for pyrazinamide (PZA) and 




Intraday (N = 5) Interday (N = 15) 
Concentration 
found (mg/L, 












PZA 3 3.11 ± 0.22 3.72 7.28 3.033 ± 0.238 1.11 7.86 
8 8.09 ± 0.09 1.15 1.12 7.976 ± 0.58 −0.29 7.27 
35 33.87 ± 0.089 −3.24 0.26 33.88 ± 1.3 −3.20 3.84 
70 72.00 ± 2.6 2.87 3.66 68.36 ± 4.67 −2.35 6.83 
INH 0.6 0.62 ± 0.027 4.18 4.38 0.602 ± 0.051 0.39 8.51 
1.6 1.59 ± 0.051 −0.58 3.21 1.54 ± 0.097 −3.39 6.28 
7 7.02 ± 0.14 0.3 2.00 6.81 ± 0.314 −2.7 4.61 
14 13.7 ± 0.21 −2.15 1.55 14.32 ± 0.82 2.28 5.73 
 
 = 340 nm  = 254 nm  = 269 nm 
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Table 2: Recovery data for pyrazinamide (PZA), 





PZA 8 92.15 
35 86.5 
70 94.37 
Mean 91.01 (RSD = 3.64%) 
INH 1.6 101.5  
7 89.67  
14 95.14  
MEAN 95 .44 (RSD = 5.07%) 
IS 100 87.28 
 
The maximum INH concentration was in the 
range of 1.6 mg/L to 11.7 mg/L (5.7 ± 2.76). 
Compared with the published reference range 
[15] of 3 mg/L to 6 mg/L, 11 patients (44 %) had 
high INH concentration, 10 patients (40 %) had 
normal INH concentration, and 4 patients (16 %) 
had low INH concentration. 
 
PZA Cmax was in the range of 29.3 mg/L to 71.4 
mg/L (49.1 ± 13.2). Compared with the published 
reference range [15] of 20 - 60 mg/L, 18 patients 
(72 %) had normal PZA concentration and 7 
patients (28 %) had high PZA concentration. No 
patient had low PZA concentration. The median 




During the development of this method, various 
chemical buffers at different concentrations and 
different pH ranges have been considered. 
However, PZA peak was best separated and 
resolved with the use of 1-hexane sulfonic acid 
sodium salt at 20 mM concentration and 2.7 pH 
adjusted with 10 % ortho-phosphoric acid. TCA 
was selected for plasma protein precipitation 
because the coupling reaction of INH with trans-
cinnamaldehyde requires an acidic medium 
[10,11,16]. In addition, PZA recovery was higher 
with TCA than with organic protein precipitants, 
such as acetonitrile or methanol. The ratio of 
TCA to plasma was selected to be 0.5:1 because 
it is the lowest ratio that yields maximum protein 
precipitation and minimum dilution of target 
compounds in supernatant [17]. TCA was used 
to precipitate plasma proteins in 10 % to 30 % 
(w/v) concentration. In this method, no 
differences between these concentrations were 
observed; thus, the lowest concentration (10 %) 
was selected. CS choices for INH and PZA were 
made based on their ranges in TB patients found 
in other studies [5–7,18,19]. QCS concentrations 
were selected based on the recommendations of 
the FDA guideline for bioanalytical method 
validation [20]. The guideline recommends the 
use of three different concentrations as QCS. 
The low-concentration QCS should be within 
three times the LLOQ. The middle-concentration 
QCS should be in the midrange of the calibration 
curve. The high-concentration QCS should 
approach the upper limit of the calibration curve. 
The coupling reaction of INH with trans-
cinnamaldehyde to produce a derivative with 
maximum UV absorption at 340 nm was first 
used by Eidus and Harnanansingh [16] in a 
spectrophotometric method. This chemical 
reaction was used in other HPLC methods 
[10,11]. However, all of these methods were 
developed for the quantification of INH alone or 
with its metabolites, and none of them can be 
used for the determination of PZA. Our method is 
suitable for the simultaneous determination of 
INH and PZA with a few simple steps of plasma 
pretreatment and short running time. These two 
advantages make this method suitable for the 
analysis of a large number of samples. 
 
The maximum INH and PZA plasma 
concentrations obtained in this study were 
consistent with the results of other studies. 
McIlleron et al [18] reported that the median Cmax 
of INH was 6.5 mg/L, and only 2 % of 142 
patients had Cmax of INH level less than 3 mg/L. 
The median Cmax of PZA was 52.7 mg/L, and 
only one patient (0.7 %) had Cmax of PZA less 
than 20 mg/L. Vij et al [19] determined that the 
mean Cmax of INH was 6.9 mg/L in 10 patients 
with pulmonary TB, whereas the mean Cmax of 
PZA was 26.7 mg/L. Chideya et al [5] observed 
that 37 and 5 % of patients had low 
concentrations of INH and PZA respectively. The 
high proportion of patients with low INH 
concentration in their study may be attributed to 
the fact that most of the patients included were 
HIV-positive. In addition, in their study, blood 
samples were collected at 1, 2 and 6 h after drug 
ingestion. In our study, 0.5 h was the most 
common Tmax for INH and PZA. In fact, a low INH 
concentration is common in studies that rely on 
one blood sample. For instance, Ray et al [21] 
reported that INH concentration in 2 h post-dose 
samples taken from 90 patients was below the 
reference range in 48 % of the patients. Moussa 
et al [11] determined that the INH concentration 
in 3 h post-dose samples was below the 
reference range in 54 % of 13 TB patients. Our 
results, together with the results of other studies 
[18,19], indicate the importance of analyzing a 
series of blood samples to obtain the maximum 
blood concentrations of INH and PZA. Relying on 
one sample taken at a specific time, such as the 
2 or 3 h post dose, is likely to yield a false high 
percentage of patients with low levels of these 
drugs, particularly INH. 
 
CONCLUSION 
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The proposed method is selective, precise, 
accurate, fast, simple and suitable for application 
in the simultaneous therapeutic drug monitoring 
of INH and PZA. A series of blood samples is 
required to measure the Cmax of INH and PZA 
accurately for clinical decision making because 
the Tmax of these drugs shows a wide variation 
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